Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A comparative evaluation of the CN-6000 haemostasis analyser using coagulation, amidolytic, immuno-turbidometric and light transmission aggregometry assays.
Int J Lab Hematol
October 2020
Haemostasis Research Unit, University College London, London, UK.
Background: The CN-6000 (Sysmex Corp.) is a new haemostasis analyser with blood coagulation, amidolytic, immuno-turbidometric and light transmission aggregometry (LTA) capabilities. Transmitted light is monitored at multiple wavelengths (340, 405, 575, 660, 800 nm), from an LED light source.
View Article and Find Full Text PDFAssay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa.
Clin Appl Thromb Hemost
July 2020
Cardiovascular Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
Andexanet alfa is a recombinant factor Xa decoy protein, designed to reverse bleeding associated with oral anti-Xa agents. Andexanet alfa is also reported to neutralize the effects of heparin-related drugs. This study focused on the neutralization profiles of unfractionated heparin (UFH), enoxaparin, and, a chemically synthetic pentasaccharide, fondaparinux by andexanet alfa.
View Article and Find Full Text PDFReversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
Clin Appl Thromb Hemost
January 2020
1 Cardiovascular Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
Recombinant coagulation factor Xa (FXa), inactivated Zh-zo, also known as andexanet alfa (AA), is a modified version of human FXa that has been developed to neutralize FXa inhibitors. We studied the reversal effect of AA for these inhibitors in various anticoagulant and thrombin generation (TG) assays. Individual aliquots of normal human plasma containing 1 µg/mL of apixaban, betrixaban, edoxaban, and rivaroxaban, were supplemented with saline or AA at a concentration of 100 µg/mL.
View Article and Find Full Text PDFFactor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum.
Clin Appl Thromb Hemost
November 2019
1 Health Sciences Division, Cardiovascular Research Institute, Loyola University Chicago, Maywood, IL, USA.
The currently available oral anti-Xa agents are claimed to produce their anticoagulant and antithrombotic effects solely by the inhibition of factor Xa. This study profiled various anti-Xa drugs in routinely used laboratory assays to demonstrate that their effects are not solely related to the anti-Xa activities. Apixaban, betrixaban, edoxaban, and rivaroxaban were obtained commercially.
View Article and Find Full Text PDFAntithrombin levels are unaffected by warfarin use.
Arch Pathol Lab Med
July 2014
From the Department of Hematology/Coagulation Services, Marshfield Labs, Marshfield (Mr Sanfelippo), the Marshfield Clinic Cancer Care at St Michaels, Stevens Point (Ms Engel), and the Department of Hematology/Oncology, Marshfield Clinic Weston Center, Weston (Dr Onitilo), Wisconsin.
Context: The results of studies among patients with antithrombin deficiency have suggested that the use of warfarin will increase the level of antithrombin.
Objective: To reevaluate the effect of warfarin on antithrombin levels using an automated amidolytic method in current use.
Design: Antithrombin levels were measured in patients who were receiving warfarin for atrial fibrillation and were compared with antithrombin levels in preoperative patients who had not received warfarin.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!